Citations

Clear

6421 citation(s) found for "Su, Christopher".

Multicenter analysis of flow diversion for recurrent/persistent intracranial aneurysms after stent-assisted coiling
Salem, Mohamed M. , Helal, Ahmed , Gajjar, Avi A. , Sioutas, Georgios S. , Heiferman, Daniel M. , Lylyk, Iván , Levine, Alex, Salih, Mira , Abbas, Rawad , Saber, Hamidreza , Lanzino, Giuseppe, Brinjikji, Waleed , Tanweer, Omar , Spiotta, Alejandro M , Park, Min S. , Dumont, Aaron S. , Kim, Louis J. , Kan, Peter , Wolfe, Stacey Q , Raz, Eytan , Shapiro, Maksim , Siddiqui, Adnan H. , Ares, William J. , Ogilvy, Christopher S. , Srinivasan, Visish M. , Starke, Robert M., Ducruet, Andrew F. , Tjoumakaris, Stavropoula , Jankowitz, Brian T. , Albuquerque, Felipe C , Nelson, Peter Kim , Riina, Howard A. , Lylyk, Pedro , Jabbour, Pascal , Burkhardt, Jan Karl, Heiferman, Daniel M , Lylyk, Ivan , Desai, Sohum , Borg, Nicholas , Brinjikji, Waleed , Spiotta, Alejandro M , Arthur, Adam Stephen , Levitt, Michael R , Kan, Peter , Hassan, Ameer E , Wolfe, Stacey Quintero , Raz, Eytan , Siddiqui, Adnan H , Ares, William J , Ogilvy, Christopher S , Tjoumakaris, Stavropoula , Jankowitz, Brian , Albuquerque, Felipe C , Jabbour, Pascal , Burkhardt, Jan‐Karl , Naamani, Kareem El , Renieri, Leonardo , Monteiro, Andre , Abdelsalam, Ahmed, Catapano, Joshua S , Lanzino, Giuseppe , Kim, Louis J. , Levitt, Michael R. , Hassan, Ameer E , Limbucci, Nicola , Colby, Geoffrey P. , Hanel, Ricardó A. , Levy, Elad I. , Thomas, Ajith J , Lopes, Demetrius K.

Mayo Clinic

Journal of NeuroInterventional Surgery | March 27, 2025 | Volume: 18 | Issue: 2 | Pages: 324-331

10.1136/jnis-2024-022422 | PMID 40139781 Get It

Background Flow-diverter stents (FDS) have become the standard of care for a wide range of intracranial aneurysms, but their efficacy/safety in the context of recurrent/recanalized aneurysms following stent-assisted coiling (SAC) is not well established. We evaluate the outcomes of FDS retreatment in a large multicenter cohort. Methods We retrospectively analyzed data from 118 patients across 22 institutions who underwent FDS retreatment for recurrent/persistent aneurysms after SAC (2008–22). The primary outcome was angiographic occlusion status at last follow-up, categorized as complete (100%), near-complete (90–99%), or incomplete (<90%) occlusion. Secondary outcomes included procedural complications and clinical outcomes measured by the modified Rankin Scale (mRS). Results A total of 118 patients (median age 57, 74.6% female) with median follow-up of 15.3 months were identified. Complete occlusion was achieved in 62.5% and near-complete occlusion in 25%. FDS deployment within the pre-existing stent was successful in 98.3% of cases. Major complications occurred in 3.4% of cases, including postoperative aneurysmal rupture with resultant mortality (1.6%) and thromboembolic events with long-term disability (1.6%). Favorable clinical outcomes (mRS 0–2) were observed in 95.1% of patients. Wider aneurysm neck diameter was a significant predictor of incomplete occlusion (adjusted OR (aOR) 1.23 per mm, P=0.044), with male sex trending towards association with non-occlusion (aOR 3.2, P=0.07), while baseline hypertension was associated with complete occlusion (aOR 0.32, P=0.048). Conclusions FDS treatment for recurrent/residual aneurysms after SAC represents a viable treatment option for these challenging cases with acceptable safety and reasonable occlusion rates, although lower than de novo FDS occlusion rates.
Are Anesthesiologists Prepared to Manage Patients With Critical Cardiac Disease?
Ladlie, Beth L., Shore‐Lesserson, Linda , Troianos, Christopher A. , Milam, Adam J. , Ladlie, Beth, Milam, Adam J , Faloye, Abimbola O. , Muehlschlegel, Jochen D

Mayo Clinic

Anesthesia & Analgesia | March 26, 2025 | Volume: 140 | Issue: 6 | Pages: e73-e75

10.1213/ane.0000000000007488 | PMID 40131818 Get It

Implementation of a Multicancer Detection (MCD) Test in a Tertiary Referral Center in Asymptomatic Patients: An 18-Month Prospective Cohort Study
Ghosh, Aditya , Dougan, Brian M. , Gilman, Elizabeth A. , Salonen, Bradley R. , Bonnes, Sara L. , Andersen, Carl , Pasha, Amirala S. , Nanda, S. , Pagel, Erin M., Verness, Christina D., Crowley, Steven D. , Ressler, Steven W. , Samadder, Jewel, Chaudhuri, Aadel A. , Sánchez, William , Croghan, Ivana T. , Stephenson, Christopher R. , Ghosh, Karthik, Hurt, Ryan T. , Gilman, Elizabeth A , Adusumalli, Jay, Andersen, Carl A, Pasha, Amirala S , Pagel, Erin M , Samadder, Jewel J., Presutti, Richard J , Sanchez, William , Croghan, Ivana T , Ghosh, Aditya K , Ressler, Steven W , Adusumalli, Jayanth , Presutti, R. John

Mayo Clinic

Journal of Primary Care & Community Health | March 26, 2025 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/21501319251329290 | PMID 40132152 Get It

Objective: Multicancer Detection (MCD) tests, such as the GRAIL Galleri, offer a novel approach to cancer screening by detecting cancer-specific methylation patterns in cell-free DNA through a single blood sample. This study evaluated an 18-month implementation of MCD testing in a tertiary ambulatory internal medicine clinic. Patients and Methods: Between June 2022 and November 2023, 2244 asymptomatic (without symptoms attributed to cancer) patients underwent MCD testing. The study focused on operational workflows, patient and physician education, and diagnostic follow-up of positive results. Standardized materials, including electronic health record (EHR) workflows, FAQs, and diagnostic pathways, were developed to facilitate implementation. Challenges included managing false positives, patient anxiety, costs, and ethical considerations. Results: Of the 2244 patients tested, 17 (0.76%) had positive results, and 15 underwent further diagnostic evaluation. Cancer was confirmed in 11 (73.3%) patients, including cases of breast, colon, esophageal, lymphoma, ovarian, and pancreatic cancers. Four patients had no identifiable malignancy despite comprehensive work-up. Conclusions: MCD testing is feasible in routine clinical workflows, with 73% of positive cases yielding cancer diagnoses. While promising, further research is required to assess long-term outcomes, cost-effectiveness, and optimal implementation strategies of cancer interception in broader healthcare settings.
The Use of Computed Tomography Densitometry for the Assessment of Emphysema in Clinical Trials: A Position Paper from the Fleischner Society
Estépar, Raúl San Jośe , Barr, R. Graham, Fain, Sean B. , Hoffman, Eric A. , Humphries, Stephen M. , Obuchowski, Nancy A. , Ryerson, Christopher J. , Bankier, Alexander A. , Crapo, James D. , Han, Meilan, Kellermeyer, Liz , Newell, John D. , Miller, Bruce E. , Nordenmark, Lars H. , Rémy‐Jardin, Martine , Silverman, Edwin K. , Washko, George R. , Lynch, David A. , San Jose Estepar, Raul , Hoffman, Eric A , Humphries, Stephen M , Tal-Singer, Ruth , Ash, Samuel Y , Barr, R. Graham, Greniér, Philippe , Kirby, Miranda , Seo, Joon Beom , Tal‐Singer, Ruth , Han, MeiLan King , Goldin, Jonathan , McCollough, Cynthia H. , Prokop, Mathias , Ohno, Yoshiharu , Strange, Charlie

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | March 24, 2025 | Volume: 211 | Issue: 5 | Pages: 709-728

10.1164/rccm.202410-2012so | PMID 40126404 Get It

Abstract Emphysema’s significant morbidity and mortality underscore the need for reliable outcome metrics in clinical trials. However, commonly accepted chronic obstructive pulmonary disease outcome measures do not adequately capture emphysema severity or progression. Computed tomography (CT) metrics have been validated as accurate indicators of pathological emphysema and predictors of chronic obstructive pulmonary disease progression, exacerbations, and mortality. This position paper reviews the evidence supporting CT densitometry as a biomarker for emphysema, establishes implementation standards, and highlights areas for future research. A systematic literature review addressed three key questions: whether CT densitometry can be used as a diagnostic biomarker of emphysema, whether CT densitometry can be used as a prognostic biomarker, and whether longitudinal change in densitometry can be used as a disease progression monitoring biomarker. Emphysema metrics, such as the percentage of low attenuation areas below −950 Hounsfield units, are validated, highly reproducible diagnostic and prognostic biomarkers. Volume-adjusted lung density is recommended for disease monitoring. Both metrics demonstrate a scan–rescan intraclass correlation coefficient of 0.99 with proper technique. The paper also discusses relevant CT physics, techniques, and sources of variation, including technical factors, physiological changes, and software analysis. Key recommendations for clinical trials include using standardized CT techniques, proper subject selection, and longitudinal evaluation with volume-adjusted lung density.
Impact of the day of the week on clinical outcomes following anterior cervical discectomy and fusion surgery
Woo, Joshua , Johnson, Sarah E. , Barrett, Connor , Bydon, Mohamad , Bisson, Erica F. , Haid, Regis W., Glassman, Steven D. , Chan, Andrew K. , Chou, Dean , Wang, Michael Y. , Knightly, John J. , Gottfried, Oren N., Shaffrey, Christopher I., Virk, Michael S., Fu, Kai-Ming, Shaffrey, Mark E., Foley, Kevin T. , Upadhyaya, Cheerag D., Potts, Eric A. , Tumialán, Luis M. , Turner, Jay D. , Uribe, Juan S. , McGirt, Matthew J., Kim, Paul K., Mummaneni, Praveen V. , Than, Khoi D. , Bergin, Stephen M., Michalopoulos, Giorgos D. , Shaffrey, Christopher I. , Virk, Michael S., Fu, Kai-Ming, Park, Paul , Kim, Paul K.

Mayo Clinic

Journal of Neurosurgery: Spine | March 22, 2025 | Volume: 42 | Issue: 6 | Pages: 737-747

10.3171/2024.11.spine24609 | PMID 40117661 Get It

OBJECTIVE Previous research suggests elective surgical procedures performed later in the week have worse outcomes. This study investigated whether the day of the week on which elective anterior cervical discectomy and fusion (ACDF) surgery was performed impacts clinical outcomes. METHODS Using data from the Quality Outcomes Database, a nationwide, multicenter prospective registry, this study included patients undergoing elective ACDF for cervical spondylosis. Patients were categorized into groups based on the surgery day (early week, Monday and Tuesday; late week, Thursday and Friday). Analyzed outcomes included postoperative complications, readmissions, reoperations, and patient-reported outcomes. Statistical methods included the independent t-test, Pearson’s chi-square test, and multivariable logistic regression. RESULTS The study analyzed 19,818 patients, with 41.7% undergoing surgery early in the week and 36.9% later. There were no significant differences in 30-day mortality, readmissions, or reoperations between the two groups. Early-week surgical procedures were associated with a higher incidence of postoperative dysphagia requiring nasogastric tubes (0.6% vs 0.3%, p = 0.02) and a higher incidence of vocal cord paralysis (0.5% vs 0.3%, p = 0.01). The data indicate a surgical selection bias with more complex surgical procedures and higher risk patients typically scheduled earlier in the week, which likely contributed to the increased rates of dysphagia. Conversely, patients who underwent operations on Fridays were more likely to be discharged on the same day compared to those earlier in the week (p = 0.02), without a significant difference in length of stay overall. Surgical procedures performed later in the week were more likely to be performed at ambulatory surgical centers rather than inpatient facilities (p < 0.01), indicating a strategic selection of healthier patients for end-of-week procedures. CONCLUSIONS The day of elective ACDF surgery does not affect mortality, readmissions, or reoperation rates. However, early-week surgical procedures may see slightly higher rates of postoperative dysphagia and vocal cord paralysis, likely due to the scheduling of more complex cases or higher risk patients during these days. Overall, the authors’ data confirm that day of surgery does not influence overall patient recovery significantly. This information is useful for surgical planning and for providing patient reassurance that the day of the week does not significantly impact surgical outcomes.
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective
Verschuur, Anna Vera D , Chen, Lin , Dijkum, Els J. Nieveen van, Luchini, Claudio, Halfdanarson, Thorvardur R, Hong, Seung‐Mo , Heaphy, Christopher M. , Hálfdánarson, Þorvarður R. , Halfdanarson, Thorvardur R , Heaphy, Christopher M , Chen, Lin , Dijkum, Els J.�M. Nieveen van , Luchini, Claudio , Singhi, Aatur Dilip , Brosens, Lodewijk A.A.

Mayo Clinic

Endocrine-Related Cancer | March 21, 2025 | Volume: 32 | Issue: 5 | Pages: No page available

10.1530/erc-24-0305 | PMID 40117346 Get It

Abstract Pancreatic neuroendocrine tumors (PanNETs) have an age-adjusted incidence of 1.5 per 100,000 people, with a notable rise in the incidence of small (≤2 cm) non-functional PanNETs (NF-PanNETs) in recent decades. While surgery is traditionally the preferred treatment for localized NF-PanNETs, active surveillance is now an accepted management strategy for tumors smaller than 2 cm due to their relatively benign behavior. However, this approach has not yet been fully integrated into routine clinical practice. There is considerable histopathological heterogeneity observed in NF-PanNETs, which results in significant variability in clinical presentation, behavior and treatment outcomes. Hence, tumor size alone does not provide sufficient certainty regarding a benign clinical course for decision-making. Although studies advocate for incorporating WHO grade into clinical prognostic assessments, this marker also has limitations. Several established tissue-based markers, such as ATRX and DAXX alterations, alternative lengthening of telomeres, and copy number variations, can be used for PanNET subtyping and correlate with metastatic risk. Combining these markers with traditional histopathological parameters may yield a more comprehensive and accurate prognostic assessment. This review discusses the advantages and limitations of current prognostication methods for small NF-PanNETs and highlights recently established prognostic markers, along with the requirements for their implementation into routine clinical practice. It also proposes practical solutions to address the challenges associated with the immediate integration of these biomarkers into routine care.
Deep learning analysis of MRI accurately detects early-stage perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis
Eaton, John E. , Welle, Christopher L. , Karlsen, Tom H. , Jørgensen, Kristin Kaasen , Folseraas, Trine , Petrovic, Kosta, Negård, Anne , Bjoerk, Ida, Abildgaard, Andreas , Gulamhusein, Aliya , Jhaveri, Kartik , Taner, Timuçin , Diwan, Tayyab S. , Diwan, Ty S, Singh, Yashbir , Venkatesh, Sudhakar K. , Smith, Byron H. , Faghani, Shahriar , Vesterhus, Mette , Gores, Gregory J. , Ilyas, Sumera I. , Heimbach, Julie K. , LaRusso, Nicholas F. , Lazaridis, Konstantinos N. , Erickson, Bradley J.

Mayo Clinic

Hepatology | March 20, 2025 | Volume: 83 | Issue: 1 | Pages: 30-39

10.1097/hep.0000000000001314 | PMID 40112296 Get It

Background and Aims: Among those with primary sclerosing cholangitis (PSC), perihilar cholangiocarcinoma (pCCA) is often diagnosed at a late stage and is a leading source of mortality. Detection of pCCA in PSC when curative action can be taken is challenging. Our aim was to create a deep learning model that analyzed MRI to detect early-stage pCCA and compare its diagnostic performance with expert radiologists. Approach and Results: We conducted a multicenter, international, retrospective cohort study involving adults with large duct PSC who underwent contrast-enhanced MRI. Senior abdominal radiologists reviewed the images. All patients with pCCA had early-stage cancer and were registered for liver transplantation. We trained a 3D DenseNet-121 model, a form of deep learning, using MRI images and assessed its performance in a separate test cohort. The study included 398 patients (training cohort n=150; test cohort n=248). pCCA was present in 230 individuals (training cohort n=64; test cohort n=166). In the test cohort, the respective performances of the model compared to the radiologists were: sensitivity 87.9% versus 50.0%, p <0.001; specificity 84.1% versus 100.0%, p <0.001; area under receiving operating curve 86.0% versus 75.0%, p <0.001. Even when a mass was absent, the model had a higher sensitivity for pCCA than radiologists (91.6% vs. 50.6%, p <0.001) and maintained good specificity (84.1%). Conclusions: The 3D DenseNet-121 MRI model effectively detects early-stage pCCA in PSC patients. Compared to expert radiologists, the model missed fewer cases of cancer.
Autoimmune Disorders of the Liver and Biliary Tract
Anderson, C. M. , Welle, Christopher L. , Ludwig, Daniel R. , Anderson, Mark , Khot, Rachita , Itani, Malak , Zulfiqar, Maria , Torbenson, Michael , Venkatesh, Sudhakar K. , Anderson, Cody M , Anderson, Mark A , Torbenson, Michael S , Venkatesh, Sudhakar K , Zulfiqar, Maria , Itani, Malak

Mayo Clinic

RadioGraphics | March 20, 2025 | Volume: 45 | Issue: 4 | Pages: No page available

10.1148/rg.240126 | PMID 40111901 Get It

Understanding the imaging appearance of autoimmune disorders of the liver and biliary tract is important to guide further workup, suggest a particular diagnosis, monitor for disease progression or response to treatment, and evaluate for complications.
Relationships between hypometabolism and both β‐amyloid and tau PET in corticobasal syndrome
Ghirelli, Alma , Goodrich, Austin W. , Stephens, Yehkyoung C. , Graff‐Radford, Jonathan , Ali, Farwa , Agosta, Federica , Jack, Clifford R. , Lowe, Val J. , Josephs, Keith A. , Whitwell, Jennifer L. , Schwarz, Chistopher G, Jack, Clifford R , Agosta, Federica , Machulda, Mary M. , Schwarz, Christopher G. , Senjem, Matthew L. , Filippi, Massimo

Mayo Clinic

Alzheimer's & Dementia | March 20, 2025 | Volume: 21 | Issue: 3 | Pages: No page available

10.1002/alz.70018 | PMID 40108988 Get It

AbstractINTRODUCTIONAlzheimer's disease (AD) pathology causes corticobasal syndrome (CBS) in 21%–50% of patients. Studies have assessed hypometabolism in CBS according to β‐amyloid (A) positron emission tomography (PET), but the understanding of the association of both AD‐tau (T) and A with hypometabolism is incomplete.METHODSThirty‐three CBS patients and 45 controls underwent fluorodeoxyglucose (FDG), flortaucipir, and Pittsburgh compound‐B PET and were classified as A± and T±. FDG‐PET uptake was extracted for 12 regions‐of‐interest in dominant (most affected) and non‐dominant hemispheres and compared across A/T groups.RESULTSA+T+ patients had greater hypometabolism in temporo‐parieto‐occipital cortices than A+T‐ and A‐T‐ groups, with no differences observed between the A+T‐ and A‐T‐ groups. FDG asymmetry was more accentuated in A+T+ patients. Medial temporal and basal ganglia metabolism were similar across AT groups.DISCUSSIONAmyloid and tau positivity contribute synergistically to hypometabolism and asymmetry in temporo‐parieto‐occipital cortices in CBS, with AD‐like patterns of hypometabolism observed only in A+T+ patients.Highlights Amyloid (A) and tau PET (T) status can be used to stratify CBS patients. A+T+ CBS patients show more hypometabolism in temporo‐parieto‐occipital cortices. Medial temporal metabolism (typical AD pattern) is similar across AT groups. Parieto‐occipital cortices should be assessed when investigating AT pathology in CBS. Amyloid and tau positivity contribute synergistically to hypometabolism and asymmetry in CBS.